Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability

Oral glucocorticoids (GCs) have been shown to be effective in reducing the inflammatory symptoms of rheumatoid arthritis, but their use is not supported by evidence in spondyloarthritis (SpA). Modified-release (MR) oral prednisone taken at bedtime has been shown to be more effective than immediate-r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug design, development and therapy development and therapy, 2016-01, Vol.10, p.3717-3724
Hauptverfasser:	Bandinelli, Francesca, Scazzariello, Francesco, Pimenta da Fonseca, Emanuela, Barreto Santiago, Mittermayer, Marcassa, Claudio, Nacci, Francesca, Matucci Cerinic, Marco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Ankylosing spondylitis Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Arthritis Cohort Studies Controlled release technology Cytokines Dosage and administration Drug dosages Drug therapy Female Glucocorticoids Humans Immune system Inflammation Inflammatory bowel disease Inflammatory diseases Male Middle Aged modified-release prednisone morning stiffness Nonsteroidal anti-inflammatory drugs Original Research Pain Pain - drug therapy Prednisolone Prednisone Prednisone - administration & dosage Prednisone - adverse effects Retrospective Studies Rheumatic diseases Rheumatoid arthritis Rheumatology Safety Short term Side effects Signs and symptoms Spondylarthritis - drug therapy Spondylarthritis - physiopathology Spondylitis Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - physiopathology spondyloarthritis Spondyloarthropathies Stiffness Substance abuse treatment Testing Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Oral glucocorticoids (GCs) have been shown to be effective in reducing the inflammatory symptoms of rheumatoid arthritis, but their use is not supported by evidence in spondyloarthritis (SpA). Modified-release (MR) oral prednisone taken at bedtime has been shown to be more effective than immediate-release prednisone taken in the morning. The efficacy of low-dose MR prednisolone in patients with SpA is unknown. This single-center cohort study retrospectively assessed the effectiveness and safety of 12-week low-dose MR prednisone (5 mg daily, bedtime administration) in GC-naïve adult patients with symptomatic axial SpA. A 50% improvement of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or a final BASDAI score of
ISSN:	1177-8881 1177-8881
DOI:	10.2147/DDDT.S115099